Open access · OA
via Europe PMC
Geroprotective Effects of Drugs Modulating Metabolic Pathways: Perspectives of Pharmacology in Anti-Aging Therapy.
Grycan M, Zyśk R, Grycan G, Jakiel G, Dudek A, Gromadzka G.
International journal of molecular sciences · 2026
Epigenetic alterations
Cellular senescence
Senolytics
Rapamycin / mTOR inhibition
Metformin
Partial reprogramming (OSK)
Human
Preclinical / animal
Review
Abstract
Aging is the strongest risk factor for chronic diseases such as cardiovascular diseases, cancer, diabetes, and neurodegenerative disorders. Advances in geroscience indicate that pharmacological modulation of conserved molecular pathways may extend healthspan(definition) and delay multimorbidity. A structured narrative review of the PubMed, Scopus, and Web of Science literature published between January 2010 and May 2026 was conducted, with seminal earlier studies retained where relevant. The review focused on molecular pathways implicated in aging, pharmacological interventions targeting these pathways, and their preclinical and clinical evaluation. Particular emphasis was placed on translational evidence, including human biomarker studies and randomized clinical trials, and on the distinction between biomarker modulation and clinically meaningful outcomes. Repurposed drugs such as metformin and mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) have among the most extensive preclinical and translational evidence, although clinical evidence for broadly applicable geroprotection remains limited. Statins, SGLT2 inhibitors, GLP-1 receptor agonists, and menopausal hormone therapy have established disease-specific or cardiometabolic benefits that may have indirect relevance to geroprotection, but direct effects on biological aging and healthspan remain unproven. Other candidates, including senolytics(definition), NAD<sup>+</sup> precursors, taurine, and epigenetic reprogramming approaches, are at different stages of translational development, with evidence ranging from promising preclinical findings to early human studies. Across interventions, a substantial gap remains between mechanistic plausibility and clinically validated geroprotection. Geroprotective pharmacology represents a promising but incompletely validated approach to extending healthspan. Major uncertainties include the absence of universally accepted biomarkers and clinical endpoints of biological aging, heterogeneity in treatment response, optimal timing and duration of interventions, and long-term safety. Future research should prioritize adequately powered randomized clinical trials integrating standardized measures of biological aging with clinically meaningful outcomes, alongside biomarker-guided patient selection, appropriate treatment timing, and careful assessment of long-term safety. The future of geroprotective medicine will depend not only on identifying additional pharmacological targets, but on demonstrating that their modulation produces durable and clinically meaningful benefits in humans.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.3390/ijms27177521
- Canonical
- link ↗
- Fetched
- 2026-10-07 MST
Cite this
APA
M, G., R, Z., G, G., G, J., A, D., & G., G. (2026). Geroprotective Effects of Drugs Modulating Metabolic Pathways: Perspectives of Pharmacology in Anti-Aging Therapy. <em>International journal of molecular sciences</em>. https://doi.org/10.3390/ijms27177521
Vancouver
M G, R Z, G G, G J, A D, G. G. Geroprotective Effects of Drugs Modulating Metabolic Pathways: Perspectives of Pharmacology in Anti-Aging Therapy. International journal of molecular sciences. 2026. doi:10.3390/ijms27177521.
BibTeX
@article{grycan2026Geropr,
title = {Geroprotective Effects of Drugs Modulating Metabolic Pathways: Perspectives of Pharmacology in Anti-Aging Therapy.},
author = {Grycan M and Zyśk R and Grycan G and Jakiel G and Dudek A and Gromadzka G.},
journal = {International journal of molecular sciences},
year = {2026},
doi = {10.3390/ijms27177521},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Expert opinion on therapeutic targets 2026
Citation only
Molecular targets for the treatment of sarcopenia: a geroscience approach.
Innovation in Aging 2021
Open access · CC-BY
Operationalizing Healthspan as an Outcome for Clinical Trials in Geroscience
International journal of general medicine 2026
Open access · OA
Research Progress of Stem Cell Therapy for Premature Ovarian Insufficiency.
Frontiers in Aging Neuroscience 2025
Open access · CC-BY
Current aspects of targeting cellular senescence for the therapy of neurodegenerative diseases
University of Padova 2018
Open access · US-GOV
Edoxaban Performance in Senior Citizen With Non-valvular Atrial Fibrillation Evaluated Per Frailty
Preprints.org 2026
Preprint · CC-BY